Citizens Jmp Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $137.00

Key Points

• Citizens JMP lowered Mirum Pharmaceuticals’ price target from $146 to $137 while maintaining a “market outperform” rating, implying roughly 29.5% upside from the $105.79 share price.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $139.80; other firms’ targets range from $140 to $165.
• Mirum’s latest quarter showed strong revenue growth of 37.9% year over year to $176.24 million, exceeding estimates, but the company reported a larger-than-expected $1.06 per-share loss and continues to face profitability pressure.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) had its price objective cut by investment analysts at Citizens Jmp from $146.00 to $137.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a "market outperform" rating on the stock. Citizens Jmp's price objective points to a potential upside of 29.50% from the company's current price.

MIRM has been the subject of a number of other reports. Morgan Stanley lifted their price objective on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an "overweight" rating in a report on Thursday, June 11th. Royal Bank Of Canada lifted their price target on shares of Mirum Pharmaceuticals from $142.00 to $148.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 7th. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a report on Monday, June 15th. HC Wainwright cut their price target on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Raymond James Financial reissued a "strong-buy" rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $139.80.

Mirum Pharmaceuticals Trading Up 1.4%

Shares of Mirum Pharmaceuticals stock opened at $105.79 on Thursday. The firm has a market cap of $6.45 billion, a PE ratio of -7.77 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. Mirum Pharmaceuticals has a 1 year low of $50.25 and a 1 year high of $130.00. The stock has a fifty day moving average price of $110.46 and a 200-day moving average price of $101.77.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. The company's revenue was up 37.9% on a year-over-year basis. Equities research analysts anticipate that Mirum Pharmaceuticals will post -2.01 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 30,000 shares of the firm's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the transaction, the senior vice president owned 3,114 shares in the company, valued at $373,680. This trade represents a 46.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 67,155 shares of company stock valued at $7,185,662. 8.32% of the stock is owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its holdings in shares of Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company's stock valued at $641,764,000 after purchasing an additional 880,505 shares during the last quarter. Vanguard Group Inc. increased its stake in Mirum Pharmaceuticals by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company's stock worth $205,065,000 after acquiring an additional 50,720 shares during the last quarter. State Street Corp raised its position in Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company's stock valued at $169,354,000 after purchasing an additional 797,088 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Mirum Pharmaceuticals by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company's stock valued at $112,196,000 after purchasing an additional 137,087 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Mirum Pharmaceuticals by 56.6% in the 4th quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company's stock valued at $97,776,000 after purchasing an additional 447,141 shares during the last quarter.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of $176.24 million, up 37.9% year over year and above the $166.33 million consensus estimate. The company also raised or reaffirmed full-year 2026 revenue guidance at $680 million-$700 million, ahead of Wall Street’s $675.1 million estimate. Mirum Pharmaceuticals Q2 earnings report
• Positive Sentiment: Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating and an average price target of $143.40, well above the recent trading level. Morgan Stanley previously raised its target to $150 and maintained an overweight rating. Mirum Pharmaceuticals analyst ratings
• Neutral Sentiment: The Q2 earnings call transcript provides additional management commentary for investors, but the supplied reports do not identify a specific new catalyst or change in the company’s development and commercialization outlook. Mirum Pharmaceuticals Q2 2026 earnings call transcript
• Negative Sentiment: Mirum posted a quarterly loss of approximately $0.80 per share on an adjusted basis, narrowly missing the $0.77 consensus estimate; the reported $1.06 per-share loss under another earnings measure was also below expectations. The loss widened from $0.12 per share a year earlier, highlighting continued profitability pressure. Mirum Pharmaceuticals Q2 loss report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth $193,733.60, reducing her direct holdings by 59.09%. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, it may be less concerning than discretionary selling, but it nevertheless adds modest selling pressure. Mirum Pharmaceuticals insider sale

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source